Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CAMPTOSAR

« Back to Dashboard

Summary for Tradename: CAMPTOSAR

Suppliers: see list1

Pharmacology for Tradename: CAMPTOSAR

Clinical Trials for: CAMPTOSAR

Panitumumab and Irinotecan for Malignant Gliomas
Status: Terminated Condition: Malignant Glioma of Brain

Irinotecan (Camptosar) in Patients With Advanced Sarcomas
Status: Completed Condition: Sarcoma

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
Status: Completed Condition: Malignant Glioma

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
Status: Recruiting Condition: Colorectal Cancer

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme
Status: Terminated Condition: Malignant Gliomas

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Recruiting Condition: Small Cell Lung Carcinoma; Non Small Cell Lung Carcinoma; Irinotecan Sensitive Cancers

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Status: Terminated Condition: Astrocytoma; Glioma; Oligodendroglioma

Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
Status: Completed Condition: Gastrointestinal Cancer; Carcinoma, Neuroendocrine

A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
Status: Recruiting Condition: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma; Malignant Astrocytoma NOS

CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
Status: Terminated Condition: Metastatic Colorectal Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
irinotecan hydrochloride
INJECTABLE;INJECTION020571Jun 14, 1996RXYes6,403,569*PED<disabled>Y<disabled>
Pfizer Inc
irinotecan hydrochloride
INJECTABLE;INJECTION020571Jun 14, 1996RXYes6,794,370*PED<disabled>Y<disabled>
Pfizer Inc
irinotecan hydrochloride
INJECTABLE;INJECTION020571Aug 5, 2010RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CAMPTOSAR

Drugname Dosage Strength RLD Submissiondate
irinotecan hydrochlorideInjection20 mg/mL, 2 mL and 5 mL vialsCamptosar7/26/2004
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology